| Literature DB >> 27845763 |
Roberta Gualdani1, Maria Maddalena Cavalluzzi2, Giovanni Lentini3, Solomon Habtemariam4.
Abstract
Citrus limonoids (CLs) are a group of highly oxygenated terpenoid secondary metabolites found mostly in the seeds, fruits and peel tissues of citrus fruits such as lemons, limes, oranges, pumellos, grapefruits, bergamots, and mandarins. Represented by limonin, the aglycones and glycosides of CLs have shown to display numerous pharmacological activities including anticancer, antimicrobial, antioxidant, antidiabetic and insecticidal among others. In this review, the chemistry and pharmacology of CLs are systematically scrutinised through the use of medicinal chemistry tools and structure-activity relationship approach. Synthetic derivatives and other structurally-related limonoids from other sources are include in the analysis. With the focus on literature in the past decade, the chemical classification of CLs, their physico-chemical properties as drugs, their biosynthesis and enzymatic modifications, possible ways of enhancing their biological activities through structural modifications, their ligand efficiency metrics and systematic graphical radar plot analysis to assess their developability as drugs are among those discussed in detail.Entities:
Keywords: anticancer; antidiabetic; antiinflammatory; antimicrobial; antioxidant; citrus limonoids; developability; insecticidal; lead compound; ligand efficiency metrics; structure-activity relationships; tetranortriterpenoids
Mesh:
Substances:
Year: 2016 PMID: 27845763 PMCID: PMC6273274 DOI: 10.3390/molecules21111530
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of citrus limonoids (CLs) of the limonin (1) biosynthetic group (aglycones and corresponding β-d-glucosides) studied in the stated period (2005–2016).
Figure 2Structures of reference compounds for citrus limonoids (CLs).
Overview of the main structural features of compounds 1–15.
| Compound | Name | Molecular Formula | n′ | n′′ | R1 | R2 | R3 | R4 | R5 | R6 | X | Y | Z | Main Functional Groups | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Limonin | C26H30O8 | 2 | 1 | O | Cycle bond | Cycle bond | O–CH=CH | Dilactone | - | ||||||
| Nomilin | C28H34O9 | 2 | 1 | Cycle bond | OAc | Cycle bond | H | Cycle bond | O–CH=CH | Dilactone, acetic ester | - | ||||
| Obacunone | C26H30O7 | 1 | 1 | Cycle bond | - | Cycle bond | H | Cycle bond | O–CH=CH | Dilactone | Dehydrated analog of | ||||
| Deacetylnomilin | C26H32O8 | 2 | 1 | Cycle bond | OH | Cycle bond | H | Cycle bond | O–CH=CH | Dilactone | Deacetyl-derivative of | ||||
| Limonexic acid | C26H30O10 | 2 | 1 | O | Cycle bond | Cycle bond | CO–O–CHOH | Dilactone, pseudoacid | Hydroxybutenolide analog of | ||||||
| Isolimonexic acid | C26H30O10 | 2 | 1 | O | Cycle bond | Cycle bond | CHOH–O–CO | Dilactone, pseudoacid | Constitutional isomer of | ||||||
| Citrusin | C28H34O11 | 2 | 1 | Cycle bond | OAc | Cycle bond | H | Cycle bond | CHOH–O–CO | Dilactone, acetic ester, pseudoacid | Hydroxybutenolide analog of | ||||
| Ichangin | C26H32O9 | 2 | 1 | OH | OH | Cycle bond | Cycle bond | O–CH=CH | Dilactone | Spiro analog of | |||||
| Isoobacunoic acid | C26H32O8 | 2 | 1 | O | H | H | Cycle bond | O–CH=CH | Lactone, carboxylic acid | Product of formal reductive cleavage of | |||||
| Deoxylimonin | C26H30O7 | 2 | 0 | O | Cycle bond | Cycle bond | O–CH=CH | Dilactone | Deoxidized analog of | ||||||
| Limonin 17-β- | C32H42O14 | 2 | 1 | O | Cycle bond | Oglc 1 | H | O–CH=CH | Lactone, carboxylic acid | 17-β- | |||||
| Obacunone 17-β- | C32H42O13 | 1 | 1 | Cycle bond | - | Cycle bond | H | Oglc 1 | H | O–CH=CH | Lactone, carboxylic acid | 17-β- | |||
| Deacetylnomilinic acid 17-β- | C32H46O15 | 2 | 1 | OH | OH | H | H | Oglc 1 | H | O–CH=CH | Dicarboxylic acid | 17-β- | |||
| Nomilinic acid 17-β- | C34H48O16 | 2 | 1 | OH | OAc | H | H | Oglc 1 | H | O–CH=CH | Dicarboxylic acid, acetic ester | Ac-derivative of | |||
| Isoobacunoic acid 17-β- | C32H44O14 | 2 | 1 | O | H | H | Oglc 1 | H | O–CH=CH | Dicarboxylic acid | 17-β- | ||||
1 Oglc: O-β-d-glucopyranosyl.
Overview of the main physico-chemical properties and biological activities of compounds 1–15.
| Compound | Name (Other Trivial Names) | CAS Number | MW | Acidity 1 | Log | Log | Most Studied Biological Activities |
|---|---|---|---|---|---|---|---|
| Limonin (citrolimonin, dictamnolactone, evodin, obaculactone) | 1180-71-8 | 470 | p | 1.66 | 1.66 | Analgesic [ | |
| Nomilin | 1063-77-0 | 514 | p | 2.47 | 2.47 | Anticancer [ | |
| Obacunone (casimirolide, obacunon, tricoccin S3) | 753-03-1 | 454 | p | 2.91 | 2.91 | Anticancer [ | |
| Deacetylnomilin (isolimonin, deacetylnomilinate) | 3264-90-2 | 472 | p | 1.57 | 1.57 | Anticancer [ | |
| Limonexic acid (limonexin, shihulimonin A, substance X) 2 | 99026-99-0 | 502 | 6 ≤ p | −0.93 | −0.7 | Anticancer [ | |
| Isolimonexic acid 3 | 113164-90-2 | 502 | 6 ≤ p | −0.93 | −0.7 | Anticancer [ | |
| Citrusin 3 | 108943-57-3 | 546 | 6 ≤ p | −0.04 | 0.24 | Anti-inflammatory [ | |
| Ichangin | 10171-61-6 | 488 | p | 0.13 | 0.13 | Antibacterial [ | |
| Isoobacunoic acid (iso-obacunoic acid) | 751-28-0 | 472 | 4 ≤ p | 2.33 | −1.03 | Antibacterial [ | |
| Deoxylimonin (desoxylimonin) | 989-23-1 | 454 | p | 2.34 | 2.34 | Analgesic [ | |
| Limonin 17-β- | 123564-61-4 | 650 | 4 ≤ p | −0.46 | −3.66 | Anticancer [ | |
| Obacunone 17-β- | 123564-64-7 | 635 | 4 ≤ p | 0.79 | −2.61 | Anticancer [ | |
| Deacetylnomilinic acid 17-β- | 125107-16-6 | 671 | p | −2.2 | −5.9 | Anticancer [ | |
| Nomilinic acid 17-β- | 125107-15-5 | 713 | p | 0.04 | −4.42 | Anticancer [ | |
| Isoobacunoic acid 17-β- | 125225-95-8 | 653 | p | 0.21 | −3.49 | Antibacterial [ |
1 Predicted data generated using the ACD/Labs Percepta Platform—PhysChem Module (ACD/Labs, Toronto, ON, Canada); 2 Experimental; 3 pKa was assumed to be similar to that of limonexic acid (5); 4 pKa value from ChemAxon (https://chemicalize.com/#/calculation).
Figure 3Precursors of citrus limonoids and proposed biogenetic relationships between congeners of the limonin (1) group.
Figure 4Structures of limonoic acid (31) and limondiol (32).
Figure 5Radar plot of ligand efficiency metrics as a graphical tool to assess developability of limonin (1) as a drug. Sub-optimal property space corresponds to the inner red hexagon showing sides marked with “zero”. Ideally, good lead compounds would be represented by areas wider than this inner hexagon. This spider plot indicates the properties of 1 that need improvement. Legend: Fsp3: fraction sp3; LRI: heterocycles/carbocycles ratio; PEI: potency efficiency index; LE: ligand efficiency; LLE: lipophilic ligand efficiency; LELP: ligand efficiency dependent lipophilicity; see text for details.
Figure 6Semisynthetic analogs of limonin (1); and nomilin (2) endowed with anti-aromatase (33–36) [46]; and anti-biofilm (33–35) [63] properties.
Figure 7Water-soluble analogs of limonin (1); and deoxylimonin (10) endowed with analgesic and anti-inflammatory properties [45].
Figure 8Radar plot of ligand efficiency metrics as a graphical tool to assess developability of limonin (1, purple area) and nomilin (2, blue-green area) as drugs. Sub-optimal property space corresponds to the inner hexagon showing red sides marked with “zero”. Ideally, good lead compounds would be represented by areas wider than this inner hexagon. This spider plot indicates that 1 should be preferred to 2 as a lead compound. Legend: Fsp3: fraction sp3; LRI: heterocycles/carbocycles ratio; PEI: potency efficiency index; LE: ligand efficiency; LLE: lipophilic ligand efficiency; LELP: ligand efficiency dependent lipophilicity; see text for details.
Figure 9Radar plot of ligand efficiency metrics (LEM) as a graphical tool to assess developability of limonin (1, blue area) and obacunone (3, yellow area) as anticancer agents. Sub-optimal property space corresponds to the inner hexagon showing red sides marked with “zero”. Ideally, good lead compounds would be represented by areas wider than this inner hexagon. This spider plot indicates that 1 should be preferred to 3 as a lead compound. Legend: Fsp3: fraction sp3; LRI: heterocycles/carbocycles ratio; PEI: potency efficiency index; LE: ligand efficiency; LLE: lipophilic ligand efficiency; LELP: ligand efficiency dependent lipophilicity; see text for details.
Figure 10Structures of obacunone oxime (39) and two of its ester derivatives (40,41) endowed with high larvicidal activity [80].
Figure 11Radar plot of ligand efficiency metrics (LEM) as a graphical tool to assess developability of limonin (1, blue area) and limonexic acid (5, magenta area) as anticancer agents. Sub-optimal property space corresponds to the inner hexagon showing red sides marked with “zero”. Ideally, good lead compounds would be represented by areas wider than this inner hexagon. This spider plot indicates that 5 should be preferred to 1 as a lead compound. Legend: Fsp3: fraction sp3; LRI: heterocycles/carbocycles ratio; PEI: potency efficiency index; LE: ligand efficiency; LLE: lipophilic ligand efficiency; LELP: ligand efficiency dependent lipophilicity; see text for details.
Figure 12Formation of limonin (1) and its epimer epilimonin (41) from limonin 17β-d-glucopiranoside (11) via a furan-3-ylidene cationic intermediate (42); Glc = β-d-glucopyranosyl.
Figure 13Structures of two new pseudoacids isolated from Citrus sudachi.
Figure 14Structures of ichanexic acid (45) and isolimonic acid (46).
Figure 15Structures of limonoate A-ring lactone (LARL, 47) and nomilinoate A-ring lactone (NARL, 48).
Figure 16Structures of limonoid glucosides isolated from C. species through recently developed methodologies.
Figure 17Structures of limonin (1); and obacunone (3) metabolites identified in liver microsomes.